News · 26 weeks81-45%
2026-03-012026-08-23
Mix3990d
- Insider27(69%)
- Other4(10%)
- SEC Filings4(10%)
- Analyst2(5%)
- Earnings2(5%)
Latest news
25 items- INSIDERDirector Kliman Gilbert H exercised 2,500 shares at a strike of $25.77 and sold $475,000 worth of shares (2,500 units at $190.00) (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- PRGlaukos Announces Participation in Wells Fargo Healthcare ConferenceGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the
- INSIDERPRESIDENT & COO Gilliam Joseph E sold $10,784,659 worth of shares (60,000 units at $179.74) and exercised 60,000 shares at a strike of $52.94 (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERSVP & CHIEF FINANCIAL OFFICER Thurman Alex R. sold $3,602,600 worth of shares (20,000 units at $180.13) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $33.81 (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Wen Leana sold $88,006 worth of shares (525 units at $167.63), decreasing direct ownership by 2% to 21,092 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- SECGlaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - GLAUKOS Corp (0001192448) (Filer)
- SECSEC Form 10-Q filed by Glaukos Corporation10-Q - GLAUKOS Corp (0001192448) (Filer)
- SECGlaukos Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - GLAUKOS Corp (0001192448) (Filer)
- PRGlaukos Announces Second Quarter 2026 Financial ResultsGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include: Record net sales of $185.6 million in Q2 2026 increased 50% year-over-year on a reported basis and 49% year-over-year on a constant currency basis. Glaucoma record net sales of $155.2 million in Q2 2026 increased 50% year-over-year. U.S. Glaucoma record net sales of $118.5 million in Q2 2026 increased 64% year-over-year. Gross margin of approximately 82% and non-GAAP gross margin of approxi
- ANALYSTUBS initiated coverage on GlaukosUBS initiated coverage of Glaukos with a rating of Neutral
- PRGlaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShuntGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO™ MicroShunt in adult patients with primary open-angle glaucoma (POAG) who failed previous medical and surgical treatment. The PRESERFLO MicroShunt is a novel, ab-externo glaucoma drainage device designed to lower intraocular pressure (IOP). Constructed from a proprietary, biocompatible material known as SIBS [poly(styrene-block-isobutylene-block-styrene)], the PRESERFLO MicroShunt is an 8.5
- INSIDERSVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,600,000 worth of shares (10,000 units at $160.00) as part of a pre-agreed trading plan (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERSVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,550,000 worth of shares (10,000 units at $155.00) as part of a pre-agreed trading plan (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERSVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,500,000 worth of shares (10,000 units at $150.00) as part of a pre-agreed trading plan (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERCHIEF DEVELOPMENT OFFICER Navratil Tomas sold $99,567 worth of shares (716 units at $139.06) as part of a pre-agreed trading plan, decreasing direct ownership by 0.81% to 87,634 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- PRGlaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29Conference Call and Webcast Scheduled for 1:30 p.m. PTGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release second quarter 2026 financial results after the market close on Wednesday, July 29, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 29, 2026.A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-461-5787 (U.S.) or 585-542-9983 (Internat
- ANALYSTH.C. Wainwright initiated coverage on Glaukos with a new price targetH.C. Wainwright initiated coverage of Glaukos with a rating of Buy and set a new price target of $168.00
- INSIDERCHAIRMAN & CEO Burns Thomas William covered exercise/tax liability with 4,059 shares, decreasing direct ownership by 6% to 68,967 units (SEC Form 4) to satisfy withholding obligation4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERPRESIDENT & COO Gilliam Joseph E covered exercise/tax liability with 1,056 shares, decreasing direct ownership by 1% to 72,363 units (SEC Form 4) to satisfy withholding tax4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERCHIEF DEVELOPMENT OFFICER Navratil Tomas covered exercise/tax liability with 483 shares, decreasing direct ownership by 0.54% to 88,350 units (SEC Form 4) to satisfy withholding tax4 - GLAUKOS Corp (0001192448) (Issuer)
- PRGlaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex BlepharitisGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment of Demodex blepharitis. GLK-321 is an investigational drug candidate using Glaukos’ proprietary iLution platform, a novel ophthalmic drug-delivery system utilizing patented, cream-based drug formulations applied to the outer surface of the eyelids to enable dropless transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. The platform is designed to
- INSIDERAmendment: SEC Form 4 filed by Director Foley Mark J4/A - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Wen Leana4/A - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Stapley Marc4/A - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Weisner Aimee S4/A - GLAUKOS Corp (0001192448) (Issuer)
GKOS FAQ
7 questionsWhat does Glaukos Corporation do?
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure...Where does GKOS stock trade?
Glaukos Corporation (GKOS) is listed on NYSE.What sector and industry is GKOS in?
Glaukos Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Glaukos Corporation go public?
Glaukos Corporation (GKOS) completed its IPO in 2015.What are analysts saying about GKOS?
Glaukos Corporation has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral on 2026-07-28.What companies are similar to GKOS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare GKOS side-by-side with any of them on Quantisnow.How can I track GKOS on Quantisnow?
Quantisnow aggregates Glaukos Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GKOS to receive live email and push alerts on every new disclosure.